PCM
BIVI icon

Prelude Capital Management’s BioVie BIVI Stock Holding History

Prelude Capital Management’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129K Hold
92,063
– – 0.01% 1003
2025
Q4 		$107K Sell
92,063
-52,699
-36% -$84.8K 0.01% 1176
2025
Q3 		$275K Buy
+144,762
New +$586K 0.02% 775

Other funds holding BIVI

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Prelude Capital Management's BIVI Position: Q1 2026 in Review

Prelude Capital Management held its BioVie (BIVI) position steady in Q1 2026 at 92,063 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #1003.

Prelude Capital Management first reported a position in BIVI in Q3 2025 and has held it in 3 quarters since. The position peaked at $275K in Q3 2025. 33 funds tracked by Wall St. Rank hold BIVI as of Q1 2026.

  • Prelude Capital Management held 92,063 shares of BioVie worth $129K as of Q1 2026.
  • Prelude Capital Management left its BioVie share count unchanged in Q1 2026.
  • BioVie made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1003 holding.
  • Prelude Capital Management first reported a position in BioVie in Q3 2025 and has held it in 3 quarters since.
  • Prelude Capital Management's BioVie position peaked at $275K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held BioVie as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.